Bendamustine as Second-Line Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer

Completed · Phase 2

Conditions studied: Lung Cancer

In brief

RATIONALE: Drugs used in chemotherapy, such as bendamustine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well bendamustine works as second- or third-line therapy in treating patients with relapsed or refractory small cell lung cancer.

Key facts

Study ID

NCT00984542

Run by

Vanderbilt-Ingram Cancer Center

People needed

50

Starts

2009-09-01

Expected to finish

2012-09-01

Last updated by the study team

2014-03-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Hardin Memorial Hosptial — Elizabethtown, Kentucky, United States
• The Jones Clinic - Germantown — Germantown, Tennessee, United States
• Jackson-Madison County Hospital — Jackson, Tennessee, United States
• Baptist Regional Cancer Center at Baptist Riverside — Knoxville, Tennessee, United States
• Vanderbilt-Ingram Cancer Center - Cool Springs — Nashville, Tennessee, United States
• Vanderbilt-Ingram Cancer Center — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.